

AlloWrap[®]

AMNIOTIC MEMBRANE

Doing More with Surgical Barriers




Surgical Barrier

AlloWrap® and AlloWrap® Dry are human amniotic membrane allografts designed to be a barrier following surgical repair.

Amniotic membrane is immune-privileged, so the body does not reject it by forming antibodies.¹ AlloSource carefully processes this tissue into a shelf stable, easy to manipulate allograft, available moist or dry depending on surgeon preference.


- Provides an adhesion barrier between tissues
- Shown to minimize inflammation and control excess scar formation^{1,2}
- Contains bioactive proteins and growth factors¹
- Processed without the chorion layer, reducing thickness that may minimize mass effect³



Balanced Healing

Amniotic membrane contains growth-promoting and growth-inhibiting proteins that help the body control inflammation and scarring.

These components help create a favorable healing environment.




Staying Power

AlloWrap stays in the body past the critical phase of healing.^{4,5,6}

Many adhesion barriers dissolve in the body after a few days and do not remain during the cell proliferation phase. This may result in adhesions occurring early in the healing process, reducing their effectiveness.

AlloWrap has been shown to remain in the body through the proliferation phase and into the remodeling phase.




Versatile Application


AlloWrap is processed to simplify use in surgery.

- Two configurations including moist and dry to support open or minimally invasive procedures
- Dual sided to prevent misorientation
- May be sutured as directed by the surgeon
- Adaptable handling, including through tubular retractors*

*Moist AlloWrap is packaged with sterile backing material on both sides, do not implant backing material.



Nerve wrapped with AlloWrap



Spinal dura with AlloWrap Dry

ORDER NOW

800. 557. 3587

AlloWrap® AMNIOTIC MEMBRANE

LENGTH	WIDTH	AREA	REF/PRODUCT #
2 cm	2 cm	4 cm ²	70120004
2 cm	4 cm	8 cm ²	70120008
4 cm	4 cm	16 cm ²	70120016
4 cm	8 cm	32 cm ²	70120032

AlloWrap® Dry AMNIOTIC MEMBRANE

LENGTH	WIDTH	AREA	REF/PRODUCT #
2 cm	2 cm	4 cm ²	70220204
2 cm	4 cm	8 cm ²	70220208
4 cm	4 cm	16 cm ²	70220216
4 cm	8 cm	32 cm ²	70220232

AlloSource, one of the largest human tissue providers, honors tissue donors by creating innovative dermis, cartilage, tendon, fascia, bone and amnion allografts to help heal patients. Since 1994, we have continued to advance our allografts to improve patient outcomes, serving as a trusted tissue partner to the medical community. Learn more at allosource.org.

AlloWrap® is regulated by the FDA under 21 CFR Part 1271 Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). AlloSource® is registered with the FDA as a tissue establishment and accredited by the American Association of Tissue Banks.

The AlloWrap family of products are covered by one or more of the following US patents: 9,795,707; 9,616,152; 9,480,549; 9,358,320

REFERENCES

1. Mamede A, et al. Amniotic membrane: From structure and functions to clinical applications. *Cell Tissue Research*. 2012; 349(2):447 - 458.
2. Patel VR, et al. Dehydrated human amnion/chorion membrane allograft nerve wrap around the prostatic neurovascular bundle accelerates early return to continence and potency following robot-assisted radical prostatectomy: Propensity score-matched analysis. *European Urology*. 2015; 67(6):977 - 980.
3. Carucci L. Dysphagia secondary to anterior cervical fusion: Radiologic evaluation and findings in 74 patients. *American Journal of Roentgenology*. 2015; (204):768 - 775.
4. Duncan J. Clinical experience with AlloWrap DS amniotic membrane used as a barrier to minimize adhesions following spinal surgery. *AlloSource White Paper*. 2019; 00098 - LIT [002].
5. Samaniego A. AlloWrap surgical barrier remains in the body through the cell proliferation phase of the healing process while other surgical barriers are resorbed. *AlloSource White Paper*. 2013; M8S0052.00.
6. Nakagawa H, et al. Application of amniotic membrane allograft in the treatment of foot and ankle pathologies: A review of the basic science and clinical evidence. *Journal of Foot and Ankle Surgery*. 2023; 10(1):209 - 2012.
7. Hardy M. The biology of scar formation. *Physical Therapy*. 1989; (69):1014 - 1024.
8. Spoerl E, et al. Cross-linking of human amniotic membrane by glutaraldehyde. *Ophthalmic Research*. 2004; 36(2):71 - 77.
9. Robertson D, et al. Adhesion prevention in gynecological surgery. *Journal of Obstetrics and Gynecology*. 2010; 243(6):598 - 602.
10. Samaniego A. Human amniotic tissue as an anti-adhesion, anti-fibrotic barrier in an ovine spinal laminectomy model. *AlloSource White Paper*. 2011; M1S0979.00.



6278 S Troy Cir
Centennial, CO 80111
USA

MAIN 720. 873. 0213

allosource.org